Bain Capital Life Sciences Investors LLC acquired a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 2,295,322 shares of the company's stock, valued at approximately $37,735,000. Upstream Bio comprises approximately 4.4% of Bain Capital Life Sciences Investors LLC's portfolio, making the stock its 8th biggest holding. Bain Capital Life Sciences Investors LLC owned 4.28% of Upstream Bio as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also modified their holdings of UPB. US Bancorp DE purchased a new stake in Upstream Bio during the fourth quarter valued at approximately $27,000. Legal & General Group Plc purchased a new position in Upstream Bio during the fourth quarter worth $28,000. Summit Investment Advisors Inc. bought a new position in Upstream Bio during the fourth quarter valued at $30,000. Tower Research Capital LLC TRC purchased a new stake in shares of Upstream Bio in the fourth quarter valued at $47,000. Finally, Corebridge Financial Inc. bought a new stake in shares of Upstream Bio in the 4th quarter worth about $142,000.
Upstream Bio Stock Performance
NASDAQ:UPB traded down $0.57 during mid-day trading on Friday, hitting $8.39. 232,948 shares of the stock traded hands, compared to its average volume of 325,505. Upstream Bio, Inc. has a 52 week low of $5.14 and a 52 week high of $29.46. The firm's 50 day moving average is $7.87 and its two-hundred day moving average is $14.45.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
See Also
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
